News
Cancer Survivorship Conferences
- 30 March 2017
Resonance Health is actively involved in exploring and promoting awareness of the risk of iron toxicity and fatty liver in cancer survivors, which has resulted from cancer treatment regimes. We are working with healthcare providers, patient advocacy groups, health institutions, and patients, to assist with the provision of optimal patient care. Recently, we have attended two conferences targeted towards cancer survivorship; the Cancer Survivorship Summit in the UK and the Cancer Survivor Meeting in the USA.
American Society of Hematology (ASH) Annual Meeting Update
- 15 December 2016
Several presentations were delivered by independent experts at the prestigious 58th ASH Annual Meeting that summarised studies using Resonance Health’s FerriScan® technology. The studies demonstrated the broadening acceptance of FerriScan in iron monitoring and management and included results from the multicentre US TWiTCH study (click here to read the abstract) and from China’s Guangxi Medical University (click here to read the abstract).
Results Published Recommending Use of FerriScan in Sickle Cell Disease
- 10 November 2016
FerriScan has received further endorsement for the management of patients with Sickle Cell Disease (SCD) in apaper recently published by the highly respected Dr Janet Kwiatkowski team at the Children’s Hospital of Philadelphia, USA.
Resonance Health News - September 2016
- 30 September 2016
We are very pleased to provide an update of our most recent and upcoming activities. It has been a very productive quarter and we look forwards to further progressing our exciting new projects.
To view the newsletter please click here...
New FerriScan Video - A Clinician's Perspective
- 21 September 2016
We are delighted to present a short interview filmed between Resonance Health's Chief Scientific Officer, Prof. Tim St Pierre, and Dr Josu de la Fuente, a Consultant Paediatric Haematologist and Senior Lecturer at Imperial College London and Director of the Paediatric Blood and Marrow Transplant Programme. The video, filmed at the European Hematology Association (EHA) Congress 2016, discusses the clinical benefits of FerriScan.
Iron Monitoring in Cancer Survivors - Clinician Survey
- 09 September 2016
Iron Overload is increasingly recognised as a possible complication for cancer survivors who have received multiple blood transfusions during their cancer treatment. FerriScan can reliably and accurately screen for Iron Overload in cancer survivors with a history of blood transfusions, overcoming the poor sensitivity and specificity of serum ferritin and avoiding reliance on transfusion records, which can be incomplete.